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Reply from the authors
We agree with Dr. Salahudeen and Dr. Fleischmann’s
notion that more attention needs be paid to the causes
of malnutrition among dialysis patients whether they are
related to poor nutrient intake, chronic inflammatory
processes or (most likely) both [1]. We respectfully sub-
mit, however, that regarding the continued use of the
normalized treatment ratio (Kt/V) as an outcome-based
measure of dialysis dose, they have simply missed the
point.
The point rests as much on fundamental, physical anal-
ysis as it does on empirical (statistical) observation or
the realization that one need not normalize everything
to something as a ratio—an unsubstantiated conviction
that is the basis for the Doctors’ argument. The urea
Fig. 1. Kt/V plotted as function of BMI in 1151 patients on chronic
kinetic model was developed to describe the concentra-hemodialysis (used with permission of the International Society of Ne-
phrology [4]). tion profile of blood urea nitrogen (BUN) during a dial-
ysis cycle presuming that a substance like BUN was a
direct uremic toxin [2]. Sargent and Gotch developed
the mathematical model,
Table 1. Cox proportional hazard analysis based on body
mass-based classification: Relative risk of dying (RR) in relation
to under-dialysis V
dC
dt
5 G 2 KC
RR (relative
BMI N to Kt/V $ 1.2) 95% CI P where V 5 the volume of urea distribution presumed to
#20 138 0.49 (0.07; 3.65) 0.49 be total body water, C 5 BUN concentration, t 5 a time
21–30 722 1.74 (0.99; 3.06) 0.05 interval, G 5 the urea generation rate, and K 5 total
31–40 241 2.80 (1.19; 6.58) 0.02
urea clearance—usually the sum of dialyzer and renal.40 50 3.05 (0.19; 48.75) 0.43
clearance during dialysis and renal clearance only duringTable used with permission from [4].
an interdialysis interval.
They solved the equation during different time periods
(dialysis and interdialysis interval) to make the model
and poor nutrition in underweight patients, and, using useful.
body weight-based dosing of hemodialysis, insuring ade- Formal logic dictates that each premise (assumption)
quate dialysis in overweight patients. upon which a model is based must be valid for its in-
tended use. If one or more premises are not valid forAbdulla Salahudeen and Erwin Fleischmann
University of Mississippi Medical Center, Jackson, MS, USA such use then the model is little more than a fantasy.
Without belaboring the point, because we have doneCorrespondence to Dr. Salahudeen, Department of Medicine, Univer-
that before [3], this model presumes that V is only asity of Mississippi Medical Center, 2500 North State St., Jackson, Missis-
sippi 39216, USA. bucket of water in which urea is dissolved. That premise
might be valid if the clinician is concerned simply with
REFERENCES BUN concentration. It is not valid if the use shifts to
clinical outcome because V is a proxy for body size, or1. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF: The
urea clearance 3 dialysis time product (Kt) as an outcome-based mass, that has survival associated properties of its own.
measure of hemodialysis dose. Kidney Int 56:729–737, 1999
Logically speaking, Drs. Salahudeen and Fleischmann2. Gotch FA, Sargent JA: A mechanistic analysis of the National
Cooperative Dialysis Study (NCDS). Kidney Int 28:526–534, 1985 must either argue that V is no more than a diluent for
3. Depner TA: Assessing adequacy of hemodialysis: Urea modeling. urea or must accept the conclusion that the model upon
Kidney Int 45:1522–1535, 1994
which they base their belief and build their case is flawed.4. Salahudeen A, Fleischmann E, Bower J: Impact of lower deliv-
ered Kt/V on the survival of overweight patients on hemodialysis. The real danger of their belief, however, is revealed
Kidney Int 56:2254–2259, 1999 by their often-said notion that, “. . . the Kt/V truthfully
5. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahu-
reflects overdialysis in underweight patients . . .” (em-deen AK: Influence of excess weight on mortality and hospital stay
in 1346 hemodialysis patients. Kidney Int 55:1560–1567, 1999 phasis added). Their own data table shows that there
was no relationship between Kt/V and death risk among
low BMI patients (RR 95% CI 5 0.07 to 3.65). Kt/V
was not associated with risk among high BMI patientsÓ 2000 by the International Society of Nephrology
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either (95% CI 5 0.19 to 48.75) and was barely so in tor for the excessive incidence of cardiovascular disease
(CVD) among dialysis patients, while calcitriol mightthe other two groups. Do the authors really recommend
reducing dialysis exposure (lower K and/or shorter t) for have an ameliorating effect [1]. I believe there is no
small and undernourished patients based on such weak evidence from controlled trials with clinical end points
information? for such a beneficial effect of vitamin D in these patients
Consider a 90-pound, malnourished adult female with (and very few trials with any clinical end points at all).
a V of 20 liters. Should clinicians be satisfied with total Referring to Milliner et al [2], they make the statement
treatment exposure of only 24 L/Rx because Kt/V 5 that excessive intake of vitamin D may lead to arterial
1.2? Existing information suggests that she would then calcification. This may not be a very practical definition
be at risk from both under-nutrition and under-dialysis of excessive intake. In fact, that article showed increasing
[4]. Further to the point, should clinicians reduce K and/ prevalence of systemic calcification as a function of
or t for a robust 70 kg male treated at Kt/V 5 1.2 if he any use of calcitriol [2]. A recent article found the
later becomes ill, losing substantial body mass, simply 1,25(OH)2D3 concentration to be the most important
to preserve Kt/V 5 1.2? The Doctors’ argument suggests predictor of progressive vascular calcification among
that doing otherwise would lead to “over-dialysis.” long time survivors on hemodialysis [3]. As the only
Finally, some legislators and regulators have suggested alternative to transplantation, increased dialysis may im-
that payment be denied for dialysis treatment if Kt/V , prove the positive phosphorus balance of current dialysis
1.2 in addition to other possible sanctions. That would patients [4]. Perhaps that would be the best way to pre-
apply mostly to larger patients. Should Medicare in the venting vitamin D and PTH related problems while
United States then refuse or reduce payment if Kt/V . maintaining a healthy nutrition, and so provide for long-
1.2 (mostly for smaller patients) because such treatment term survival (without calcitriol) as reported from Tas-
constitutes unnecessary “over-dialysis” and government sin, France.
rules forbid payment for unnecessary treatment? Thus, We might not be currently lacking the clinical stud-
we see emerging from the views expressed by Drs. Sala- ies—and be overwhelmed with experimental ones—if
hudeen and Fleischmann a number of currently implausi- those reviewing the individual parts of this patchwork
ble clinical (and possibly regulatory) strategies because constituting today’s dialysis therapy more appropriately
the mathematical model upon which they base their be- viewed the whole management of ESRD as perspective.
lief is not appropriate to the clinical context for which Troels Ring
it is used. Aalborg, Denmark
Edmund G. Lowrie
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Therapy for cardiovascular Reply from the authors
To the Editor: In his letter regarding our paper indisease in dialysis patients Kidney International reviewing the effects of parathyroid
hormone and vitamin D on cardiovascular disease inTo the Editor: Examining a number of experimental
chronic renal failure [1], Dr. Ring is surprised that theand observational studies, Rostand and Dru¨eke recently
burden of cardiovascular disease renal failure persists de-suggested that parathyroid hormone might be a risk fac-
spite the widespread use of active vitamin D in the man-
agement of hyperparathyroidism and hypocalcemia in
end-stage renal disease. As we noted, although some clini-Ó 2000 by the International Society of Nephrology
